#BioInsights

資誠 (PwC Taiwan) 's Health Industries Practice has recently released a report titled 2024 Outlook: Global M&A Trends in Health Industries. The report projects an increase in M&A activities in #pharmaceuticals and life sciences (#PLS) and #healthcare services (#HCS) this year. It identifies GLP-1 drugs (GLP-1 agonists), CROs/CDMOs and #MedTech companies with strong cash flows, and Artificial intelligence (#AI) as M&A hot spots. This trend is reflected in recent acquisitions by 北極星藥業股份有限公司(北極星藥業集團) and Bora Pharmaceuticals in Taiwan.

As dealmaking challenges ease, competition for innovative technologies is intensifying, which is expected to propel health industries' M&A forward in 2024. According to PWC's 27th Annual Global CEO Survey, 54% of Health Industries CEOs plan to undertake at least one acquisition in the next three years.

Stay updated with #Globalbio for more #biotech news and insights!
https://lnkd.in/gBAtWZdQ